A
Anthony M. Turkiewicz
Researcher at University of Alabama at Birmingham
Publications - 11
Citations - 4060
Anthony M. Turkiewicz is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Psoriatic arthritis & Rheumatoid arthritis. The author has an hindex of 8, co-authored 10 publications receiving 3637 citations.
Papers
More filters
Journal ArticleDOI
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone,Peter A. Merkel,Robert Spiera,Philip Seo,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Anthony M. Turkiewicz,Nadia K. Tchao,Lisa Webber,Linna Ding,Lourdes P. Sejismundo,Kathleen Mieras,David Weitzenkamp,David Ikle,Vicki Seyfert-Margolis,Mark Mueller,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Ulrich Specks +28 more
TL;DR: Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease.
Journal ArticleDOI
American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Kenneth G. Saag,Gim Gee Teng,Nivedita M. Patkar,Jeremy Anuntiyo,Catherine Finney,Jeffrey R. Curtis,Harold E. Paulus,Amy S. Mudano,Maria Pisu,Mary Elkins-Melton,Ryan C. Outman,Jeroan J. Allison,Maria Suarez Almazor,S. Louis Bridges,W. Winn Chatham,Marc C. Hochberg,Catherine H. MacLean,Ted R. Mikuls,Larry W. Moreland,James O'Dell,Anthony M. Turkiewicz,Daniel E. Furst +21 more
TL;DR: Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient.
Journal ArticleDOI
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash,Bruce Kirkham,Masato Okada,Proton Rahman,B. Combe,Gerd Burmester,David H. Adams,Lisa Kerr,Chin Lee,Catherine L Shuler,Mark C. Genovese,Khalid Ahmed,Jeffrey Alper,Nichol Barkham,Ralph E. Bennett,Francisco Javier Blanco Garcia,Ricardo Blanco Alonso,Howard B. Blumstein,Michael S. Brooks,Gerd R Burmester,Patricia Cagnoli,Paul H. Caldron,Alain Cantagrel,Der Yuan Chen,Melvin Churchill,Christine E Codding,Peter M.G. Deane,Jose Del Giudice,Atul Deodhar,Rajat K. Dhar,Eva Dokoupilova,Rita M. Egan,Andrea Everding,Eva Galíndez,David H. Goddard,Alice B. Gottlieb,Philippe Goupille,Robert M. Griffin,Ramesh C. Gupta,Stephen B. Hall,Kalpita Hatti,Mary P. Howell,Yu-Huei Huang,Ramina Jajoo,Namieta M. Janssen,Uta Kiltz,Alan Kivitz,Steven J. Klein,Mariusz P. Korkosz,Roshan Kotha,Joel M. Kremer,Cummins Lue,José Luis Marenco de la Fuente,Helena Marzo-Ortega,Jordi Gratacós Masmitjà,Philip J. Mease,Pier Luigi Meroni,Eric C. Mueller,Anupama C. Nandagudi,Antonio Fernández-Nebro,Clark M. Neuwelt,Ana Maria Orbai,Meera R. Oza,Deborah L. Parks,Debendra Pattanaik,Maria Rell-Bakalarska,David H. Rosmarin,Euthalia Roussou,Anna I. Rychlewska-Hanczewksa,David H. Sikes,Michael T. Stack,Prashanth Sunkureddi,Hasan Tahir,Diamant Thaçi,Tsen-Fang Tsai,Anthony M. Turkiewicz,Leonore Unger,Raúl Veiga Cabello,Ulf Wagner,Cheng Chung Wei,Alvin F. Wells,Peter Youssef,Agnieszka Zielinska +82 more
TL;DR: Both the 2-week and 4-week ixekizumab dosing regimens improved the signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate response to tumour necrosis factor inhibitors, with a safety profile consistent with previous studies investigating ixeksedumab.
Journal ArticleDOI
Psoriatic arthritis: Current concepts on pathogenesis‐oriented therapeutic options
TL;DR: A subset of patients with PsA fail to respond to conventional therapies and to anti–tumor necrosis factor (anti-TNF) agents that are currently approved for the treatment of PsA, underscoring the diverse mechanisms likely to be at play in these heterogeneous phenotypic subtypes ofPsA.
Journal ArticleDOI
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
Philip J. Mease,A. Deodhar,Roy Fleischmann,Jürgen Wollenhaupt,Dafna D. Gladman,P Leszczyński,P Vitek,Anthony M. Turkiewicz,Majed Khraishi,Oliver FitzGerald,Robert Landewé,M. de Longueville,Bengt Hoepken,Luke Peterson,D. van der Heijde +14 more
TL;DR: CZP efficacy was maintained to week 96 with both dose regimens and in patients with/without prior anti-TNF exposure, with no new safety signals observed with increased exposure.